Pyxis Oncology is a preclinical oncology company based in Boston, Massachusetts. They focus on developing a portfolio of antibody therapeutics that target tumor cells and address cancer's underlying pathologies. By analyzing tumor-infiltrating lymphocytes and tumor cell signaling pathways, they aim to create novel antibody-based immunotherapies. Founded in 2019, Pyxis Oncology is dedicated to transforming the lives of cancer patients by improving treatment outcomes through their differentiated biologics. They believe that their antibody-drug conjugates and immunotherapies have the potential to address challenging cancers and overcome immune suppression.